Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | Y823D |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | KIT Y823D lies within the protein kinase domain of the Kit protein (UniProt.org). Y823D confers a gain of function on Kit, as indicated by constitutive phosphorylation of Kit in cultured cells (PMID: 14695343, PMID: 20633291). |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT Y823D KIT mutant KIT exon17 KIT Y823D |
Transcript | NM_000222.3 |
gDNA | chr4:g.54733175T>G |
cDNA | c.2467T>G |
Protein | p.Y823D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_005265741.1 | chr4:g.54733175T>G | c.2467T>G | p.Y823D | RefSeq | GRCh38/hg38 |
XM_005265741 | chr4:g.54733175T>G | c.2467T>G | p.Y823D | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54733175T>G | c.2467T>G | p.Y823D | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54733175T>G | c.2467T>G | p.Y823D | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54733175T>G | c.2467T>G | p.Y823D | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54733175T>G | c.2467T>G | p.Y823D | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT Y823D | Advanced Solid Tumor | sensitive | Motesanib Diphosphate | Preclinical - Cell culture | Actionable | In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT Y823D in culture (PMID: 20633291). | 20633291 |
KIT Y823D | Advanced Solid Tumor | sensitive | Nintedanib | Preclinical - Cell culture | Actionable | In a preclinical study, Ofev (nintedanib) inhibited Kit autophosphorylation and proliferation of transformed cells expressing KIT Y823D in culture (PMID: 35194937). | 35194937 |
KIT Y823D | melanoma | predicted - sensitive | Ripretinib | Case Reports/Case Series | Actionable | In a Phase I trial, Qinlock (ripretinib) treatment resulted in a complete response in a patient with metastatic melanoma harboring KIT Y823D (PMID: 35753087; NCT02571036). | 35753087 |